Country: Canada
Language: English
Source: Health Canada
LOPERAMIDE HYDROCHLORIDE
PHARMASCIENCE INC
A07DA03
LOPERAMIDE
2MG
TABLET
LOPERAMIDE HYDROCHLORIDE 2MG
ORAL
100/500 CAPLETS
OTC
ANTIDIARRHEA AGENTS
Active ingredient group (AIG) number: 0111332001; AHFS:
MARKETED
1996-09-12
_pms-LOPERAMIDE & pms-LOPERAMIDE HYDROCHLORIDE SOLUTION Product Monograph _ _Page 1 of 38 _ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PMS-LOPERAMIDE Loperamide Hydrochloride Tablets Caplet, 2 mg, oral USP and PMS-LOPERAMIDE HYDROCHLORIDE SOLUTION Loperamide Hydrochloride Oral Solution Solution, 0.2 mg / mL, Oral USP Antidiarrheal agent PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Canada H4P 2T4 www.pharmascience.com Date of Initial Authorization: pms-LOPERAMIDE HYDROCHLORIDE SOLUTION: June 2, 1993 pms-LOPERAMIDE August 2, 1996 Date of Revision: June 26, 2023 Submission Control Number: 272133 _pms-LOPERAMIDE & pms-LOPERAMIDE HYDROCHLORIDE SOLUTION Product Monograph _ _Page 2 of 38 _ _ _ RECENT MAJOR LABEL CHANGES 5 OVERDOSAGE, Addition of drug withdrawal syndrome 06/2022 7 WARNINGS AND PRECAUTIONS, Addition of drug withdrawal syndrome 06/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ....................................................................................................... 2 TABLE OF CONTENTS ......................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................ 4 1 INDICATIONS ........................................................................................................................ 4 1.1 Pediatrics ........................................................................................................................... 4 1.2 Geriatrics ............................................................................................................................ 4 2 CONTRAINDICATIONS ........................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ..................................................................... Read the complete document